PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 1 October 2013 - Ablynx [Euronext Brussels: ABLX] today
announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from Gimv NV and Biotech Fonds
Vlaanderen NV.
The above shareholders notified that they have dropped below the 5% threshold
and now hold 2,208,702 Ablynx shares, which represent 4.53% of the current
48,802,115 outstanding shares of Ablynx.
Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life
Sciences 2004 NV. Gimv NV (929,473 voting rights), Adviesbeheer Gimv Life
Sciences NV (0 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV (165,040
voting rights) and Biotech Fonds Vlaanderen NV (1,114,189 voting rights) are
acting in mutual agreement. The Flemish Region in Belgium is the ultimate
shareholder of Biotech Fonds Vlaanderen NV.
Full versions of all transparency notifications are available on the website of
Ablynx, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and six Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx(at)consilium-comms.com
press release in pdf format:
http://hugin.info/137912/R/1732864/579842.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1732864]
Unternehmensinformation / Kurzprofil:
Datum: 01.10.2013 - 18:00 Uhr
Sprache: Deutsch
News-ID 301867
Anzahl Zeichen: 3490
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
